0001209191-18-064319.txt : 20181228 0001209191-18-064319.hdr.sgml : 20181228 20181228162112 ACCESSION NUMBER: 0001209191-18-064319 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181226 FILED AS OF DATE: 20181228 DATE AS OF CHANGE: 20181228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PAPADOPOULOS STELIOS CENTRAL INDEX KEY: 0001202098 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35670 FILM NUMBER: 181257649 MAIL ADDRESS: STREET 1: 3 SOMERSET DRIVE SOUTH CITY: GREAT NECK STATE: NY ZIP: 11020 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Regulus Therapeutics Inc. CENTRAL INDEX KEY: 0001505512 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264738379 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10614 SCIENCE CENTER DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-202-6300 MAIL ADDRESS: STREET 1: 10614 SCIENCE CENTER DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-12-26 0 0001505512 Regulus Therapeutics Inc. RGLS 0001202098 PAPADOPOULOS STELIOS C/O REGULUS THERAPEUTICS INC. 10614 SCIENCE CENTER DRIVE SAN DIEGO CA 92121 1 0 0 0 Common Stock 2018-12-26 4 P 0 90000 0.9542 A 758672 D Common Stock 2018-12-27 4 P 0 26401 1.0401 A 785073 D The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8796 to $1.10 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.00 to $1.04 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Christopher Aker, Attorney in Fact 2018-12-28